

# HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

A

|   |   |                |
|---|---|----------------|
| <b>UTILITY<br/>PATENT APPLICATION<br/>TRANSMITTAL</b><br><small>For new nonprovisional applications under<br/>37 C.F.R. 1.53(b)</small> | Attorney Docket No.                               | WHI91-09FXA    |
|   | First Named Inventor or<br>Application Identifier | Herbert Y. Lin |
|   | Express Mail Label No.                            | EL192651127US  |

JCS550 PTO  
 09/183543  
 10/30/98

TGF-Beta Type Receptor cDNAs Encoded Products and Uses Therefor

|   |   |
|---|---|
| <b>APPLICATION ELEMENTS</b><br>See MPEP chapter 600 concerning utility patent application contents. | <b>ADDRESS TO:</b> Assistant Commissioner for Patents<br>Box Patent Application<br>Washington, D.C. 20231 |
|---|---|

|   |   |
|---|---|
| 1. <input checked="" type="checkbox"/> Fee Transmittal Form<br><i>(Submit an original, and a duplicate for fee processing)</i>  | 6. <input type="checkbox"/> Microfiche Computer Program <i>(Appendix)</i>   |
| 2. <input checked="" type="checkbox"/> Specification [Total Pages <u>42</u> ]<br><i>(preferred arrangement set forth below)</i> <ul style="list-style-type: none"> <li>- Descriptive title of the invention</li> <li>- Cross References to Related Applications</li> <li>- Statement Regarding Fed sponsored R &amp; D</li> <li>- Reference to microfiche Appendix</li> <li>- Background of the Invention</li> <li>- Summary of the Invention</li> <li>- Brief Description of the Drawings</li> <li>- Detailed Description</li> <li>- Claim(s)</li> <li>- Abstract of the Disclosure</li> </ul> | 7. <input type="checkbox"/> Nucleotide and/or Amino Acid Sequence Submission<br><i>(if applicable, all necessary)</i> <ul style="list-style-type: none"> <li>a. <input type="checkbox"/> Computer Readable Copy</li> <li>b. <input type="checkbox"/> Paper Copy (identical to computer copy)</li> <li>c. <input type="checkbox"/> Statement verifying identity of above copies</li> </ul> |

## ACCOMPANYING APPLICATION PARTS

|  |   |
|--|---|
| <input checked="" type="checkbox"/> Drawing(s) (35 U.S.C. 113) [Total Sheets <u>3</u> ]  | 8. <input type="checkbox"/> Assignment Papers (cover sheet & documents)   |
| <input checked="" type="checkbox"/> Oath or Declaration/POA [Total Pages <u>3</u> ]  | 9. <input type="checkbox"/> 37 C.F.R. 3.73(b) Statement <input type="checkbox"/> Power of Attorney<br><i>(when there is an assignee)</i>              |
| a. <input type="checkbox"/> Newly executed (original or copy)  | 10. <input type="checkbox"/> English Translation Document <i>(if applicable)</i>  |
| b. <input checked="" type="checkbox"/> Copy from a prior application (37 C.F.R. 1.63(d))<br><i>(for continuation/divisional with Box 17 completed)</i><br>[NOTE Box 5 below]   | 11. <input type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input type="checkbox"/> Copies of IDS Citations                         |
| i. <input type="checkbox"/> <u>DELETION OF INVENTOR(S)</u><br>Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. 1.63(d)(2) and 1.33(b).   | 12. <input type="checkbox"/> Preliminary Amendment  |
| 5. <input checked="" type="checkbox"/> Incorporation By Reference <i>(useable if Box 4b is checked)</i><br>The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein. | 13. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) (2)<br><i>(Should be specifically itemized)</i>                            |
|  | 14. <input type="checkbox"/> Small Entity Statement(s) <input type="checkbox"/> Statement filed in prior application, Status still proper and desired |
|  | 15. <input type="checkbox"/> Certified Copy of Priority Document(s)<br><i>(if foreign priority is claimed)</i>  |
|  | 16. <input checked="" type="checkbox"/> Other: <u>Preliminary Amendment</u>   |

17. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:

☒ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: 08 / 446,939  
 Prior application information: Examiner: D. Fitzgerald Group Art Unit: 1646

## 18. CORRESPONDENCE ADDRESS

|         |   |           |                |          |                |
|---------|---|-----------|----------------|----------|----------------|
| NAME    | Patricia Granahan                       |           |                |          |                |
|         | HAMILTON, BROOK, SMITH & REYNOLDS, P.C. |           |                |          |                |
| ADDRESS | Two Militia Drive                       |           |                |          |                |
| CITY    | Lexington                               | STATE     | MA             | ZIP CODE | 02421-4799     |
| COUNTRY | USA                                     | TELEPHONE | (781) 861-6240 | FAX      | (781) 861-9540 |

|                                       |                        |             |                         |
|---------------------------------------|------------------------|-------------|-------------------------|
| Signature                             | <u>Anne J. Collins</u> | Date        | <u>October 30, 1998</u> |
| Submitted by<br>Typed or Printed Name | Anne J. Collins        | Reg. Number | 40,564                  |

# HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

|  |                        |                |
|--|------------------------|----------------|
| <b>FEE TRANSMITTAL FOR<br/>PATENT APPLICATIONS</b> | Attorney Docket Number | WHI91-09FXA    |
|  | Application Number     |                |
|  | First Named Inventor   | Herbert Y. Lin |

CLAIM CALCULATION (includes any preliminary amendment)

| CLAIMS | (1) FOR   | (2) NUMBER FILED | (3) NUMBER EXTRA | (4) RATE                      | (5) CALCULATIONS |
|--------|---|------------------|------------------|-------------------------------|------------------|
|        | TOTAL CLAIMS<br>(37 CFR 1.16(c) or (j))                                     | 16 - 20* =       | 0                | x \$ 22 =                     | \$ 0             |
|        | INDEPENDENT CLAIMS<br>(37 CFR 1.16(b) or (i))                               | 8 - 3** =        | 5                | x \$ 82 =                     | \$ 410.00        |
|        | MULTIPLE DEPENDENT CLAIMS (if applicable) (37 CFR 1.16(d))                  |                  |                  | + \$ 270 =                    | \$               |
|        |   |                  |                  | BASIC FEE<br>(37 CFR 1.16(a)) | \$ 790           |
|        | Total of above Calculations =   |                  |                  |                               | \$ 1200.00       |
|        | Reduction by 50% for filing by small entity (37 CFR 1.9, 1.27, 1.28) =      |                  |                  |                               | \$               |
|        | TOTAL =   |                  |                  |                               | \$               |
|        | Surcharge - Late Filing of Declaration or Filing Fees (37 C.F.R. 1.16(e)) = |                  |                  |                               | \$               |
|        | Petition for Extension of Time Fee (37 C.F.R. 1.17) =                       |                  |                  |                               | \$               |
|        | Assignment Recordation Fee =<br>(only when filed with application)          |                  |                  |                               | \$               |
|        | * Reissue claims in excess of 20 and over original patent.                  |                  |                  |                               |                  |
|        | ** Reissue independent claims over original patent                          |                  |                  |                               |                  |
|        | TOTAL =   |                  |                  |                               | \$ 1200.00       |

1. Small entity status:

- a. ☐ A small entity statement is enclosed.
- b. ☐ A small entity statement was filed in the prior non-provisional application and such status is still proper and desired.
- c. ☐ Is no longer claimed.

2. ☒ A general authorization is hereby granted to charge deposit account number 08-0380 for any fees required under 37 CFR 1.16 and 1.17 in order to maintain pendency of this application. A copy of this authorization is enclosed for accounting purposes.

3. ☒ A check is enclosed for \$ 1200.00 ☐ Please charge \$ \_\_\_\_\_ to Deposit Account No. 08-0380.

4. ☐ Other: \_\_\_\_\_

|                                       |                        |             |                         |
|---------------------------------------|------------------------|-------------|-------------------------|
| Signature                             | <i>Anne J. Collins</i> | Date        | <i>October 30, 1998</i> |
| Submitted by<br>Typed or Printed Name | Anne J. Collins        | Reg. Number | 40,564                  |

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Herbert Y. Lin, Xiao-Fan Wang, Robert A. Weinberg and Harvey F. Lodish

This is a Continuation Application of:

Application No.: 08/446,939

Group: 1646

Filed:

Title: TGF- $\beta$  Type Receptor c DNAs Encoded Products and Uses ThereforDate: 10-30-98EXPRESS MAIL LABEL NO. EL1926511 2745

Assistant Commissioner for Patents

Washington, D.C. 20231

Sir:

Transmitted herewith is a Preliminary Amendment for filing in the above-identified application.

[ ] Small entity status of this application under 37 C.F.R. 1.9 and 1.27 has been established by a verified statement previously submitted.

[ ] A verified statement to establish small entity status under 37 C.F.R. 1.9 and 1.27 is enclosed.

The fee has been calculated as shown below:

(COL. 1)

(COL. 2)

(COL. 3)

|  | CLAIMS<br>REMAINING<br>AFTER<br>AMENDMENT |       | HIGHEST NO.<br>PREVIOUSLY<br>PAID FOR | PRESENT<br>EXTRA |
|--|---|-------|---------------------------------------|------------------|
| TOTAL  | 16  | MINUS | * 20                                  | 0                |
| INDEP  | 8   | MINUS | ** 3                                  | 5                |
| <input type="checkbox"/> FIRST PRESENTATION OF MULTIPLE DEP. CLAIM |   |       |                                       |                  |

SMALL ENTITY

|   | RATE  | ADDIT.<br>FEE |
|---|-------|---------------|
| X | \$11  | \$            |
| X | \$41  | \$            |
| + | \$135 | \$            |

OR

OTHER THAN  
SMALL ENTITY

|   | RATE  | ADDIT.<br>FEE |
|---|-------|---------------|
| X | \$22  | \$ 0          |
| X | \$82  | \$ 410        |
| + | \$270 | \$            |

TOTAL = \$ 0TOTAL = \$ 410

\* not fewer than 20

\*\* not fewer than 3

Please charge Deposit Account No. 08-0380 for the following fees:

|                          |  |    |   |
|--------------------------|--|----|---|
| <input type="checkbox"/> | Petition for [ ] month Extension of Time | \$ |   |
| <input type="checkbox"/> | Amendment Fee                            | \$ |   |
| <input type="checkbox"/> | Other Fees:                              |    |   |
|                          |  | \$ |   |
|                          |  | \$ |   |
|                          | TOTAL:                                   | \$ | 0 |

A check is enclosed in payment of the following fees:

|                                     |  |    |     |
|-------------------------------------|--|----|-----|
| <input type="checkbox"/>            | Petition for [ ] month Extension of Time | \$ |     |
| <input checked="" type="checkbox"/> | Amendment Fee                            | \$ | 410 |
| <input type="checkbox"/>            | Other Fees:                              |    |     |
|                                     |  | \$ |     |
|                                     |  | \$ |     |
|                                     | TOTAL:                                   | \$ | 410 |

☒ A general authorization is hereby granted to charge Deposit Account No. 08-0380 for any fees required under 37 C.F.R. 1.16 and 1.17 in order to maintain pendency of this application. A copy of this authorization is enclosed for accounting purposes.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By Anne J. Collins  
Anne J. Collins  
Registration No.: 40,564  
Telephone: (781) 861-6240  
Facsimile: (781) 861-9540

Lexington, Massachusetts 02421-4799

Dated: October 30, 1998

WH919FXA.PAM  
K:\ACOLLINS\WHI\9109FXA  
PG:AJC:kfd  
October30, 1998

PATENT APPLICATION  
Attorney's Docket No.: WHI91-09FXA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Herbert Y. Lin, Xiao-Fan Wang, Robert A. Weinberg and Harvey  
Lodish

Continuation Application of:

Application No.: 08/446,939

Filed: May 23, 1995

For: TGF- $\beta$  Type Receptor c DNAs Encoded Products and  
Uses Therefor

Date: 10-30-98

EXPRESS MAIL LABEL NO. EL19265112745

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Please amend the referenced application as follows:

In the Specification:

Please amend the title to read ---MODULATION OF TGF- $\beta$  BY TGF- $\beta$  TYPE III RECEPTOR POLYPEPTIDES---.

On page 1, line 4 of the specification, please add the following:

---RELATED APPLICATIONS

This is a Continuation of 08/446,939 filed on May 23, 1995, which is a Divisional of 08/311,703, filed September 23, 1994, which is a File Wrapper Continuation of 07/786,063, filed October 31, 1991, the entire teachings of each are incorporated herein by reference.---

On page 12, line 27, please delete "(see Example 6)".

On page 32, line 1 delete "(Figure 4)".

In the Claims:

Please cancel Claims 1-24 and 26-30. Please amend Claim 25 as follows:

25. (Amended) A method of altering the level of TGF- $\beta$  binding to TGF- $\beta$  type III receptor on the surface of a cell, comprising [combining soluble TGF- $\beta$  type III receptor with] contacting the cell with a preparation consisting essentially of a soluble polypeptide comprising the amino acid sequence of the extracellular domain of a mammalian TGF- $\beta$  type III protein, wherein the amino acid sequence of the mammalian receptor protein is:
- a) the amino acid sequence of the TGF- $\beta$  type III receptor protein of SEQ ID NO: 6 or
  - b) the amino acid sequence of a TGF- $\beta$  receptor protein encoded by mammalian DNA which hybridizes to the complement of SEQ ID NO: 5 under high stringency conditions, and
- wherein the cell is contacted[,] under conditions appropriate for binding of the soluble [TGF- $\beta$  type III receptor and] polypeptide to TGF- $\beta$  [type III].

Please add the following claims:

- 31. A method of altering the level of TGF- $\beta$  binding to TGF- $\beta$  type III receptor on the surface of a cell, comprising contacting the cell with a preparation consisting essentially of a soluble polypeptide comprising the amino acid sequence of the extracellular domain of a mammalian TGF- $\beta$  type III receptor protein, wherein the mammalian receptor protein has an amino acid sequence encoded by :
- a) the cDNA insert contained in the plasmid deposited under ATCC accession number 75127 or
  - b) a cDNA molecule which hybridizes under high stringency conditions with the complement of the coding sequence of (a), and
- wherein the cell is contacted under conditions appropriate for binding of the soluble polypeptide to TGF- $\beta$ .
32. A method of altering the level of TGF- $\beta$  binding to TGF- $\beta$  type III receptor on the surface of a cell, comprising contacting the cell with a preparation consisting essentially of a polypeptide comprising a TGF- $\beta$  binding fragment of the amino acid sequence of a mammalian TGF- $\beta$  type III receptor protein, wherein the mammalian receptor protein has an amino acid sequence selected from the group consisting of:
- a) the amino acid sequence of the TGF- $\beta$  type III receptor protein of SEQ ID NO: 6 or
  - b) the amino acid sequence encoded by a mammalian DNA which hybridizes to the complement of SEQ ID NO: 5 under high stringency conditions, and
- wherein the cell is contacted under conditions appropriate for binding of the polypeptide to TGF- $\beta$ .
33. A method of altering the level of TGF- $\beta$  binding to TGF- $\beta$  type III receptor on the surface of a cell, comprising contacting the cell with a preparation consisting essentially of a polypeptide comprising a TGF- $\beta$  binding fragment of the amino

acid sequence of a mammalian TGF- $\beta$  type III receptor protein, wherein the mammalian receptor protein has an amino acid sequence encoded by:

- a) the cDNA insert contained in the plasmid deposited under ATCC accession number 75127 or
- b) a cDNA molecule which hybridizes under high stringency conditions with the complement of the coding sequence of the cDNA insert of (a), and

wherein the cell is contacted under conditions appropriate for binding of the polypeptide to TGF- $\beta$ .

34. A method according to Claim 25, wherein the mammalian TGF- $\beta$  type III receptor protein has the amino acid sequence set forth in SEQ ID NO: 6.
35. A method according to Claim 31, wherein the mammalian TGF- $\beta$  type III receptor protein has the amino acid sequence encoded by the cDNA insert contained in the plasmid deposited under ATCC accession number 75127.
36. A method according to Claim 32, wherein the mammalian TGF- $\beta$  type III receptor protein has the amino acid sequence set forth in SEQ ID NO: 6.
37. A method according to Claim 33, wherein the mammalian TGF- $\beta$  type III receptor protein has the amino acid sequence encoded by the cDNA insert contained in the plasmid deposited under ATCC accession number 75127.
38. A method of modulating the effects of TGF- $\beta$  in a mammal, comprising administering to the mammal a polypeptide comprising the extracellular domain of a mammalian TGF- $\beta$  type III receptor wherein the mammalian receptor has an amino acid sequence selected from the group consisting of:
  - a) the amino acid sequence of the TGF- $\beta$  type III receptor protein of SEQ ID NO: 6 or



- b) the amino acid sequence encoded by a mammalian DNA which hybridizes under high stringency conditions to the complement of SEQ ID NO: 5, and

wherein the polypeptide is administered to the mammal in sufficient quantity to alter the level of TGF- $\beta$  binding to endogenous TGF- $\beta$  type II receptors, type III receptors, or both.

39. A method of modulating the effects of TGF- $\beta$  in a mammal, comprising administering to the mammal a polypeptide comprising the extracellular domain of a mammalian TGF- $\beta$  type III receptor wherein the mammalian receptor has an amino acid sequence encoded by:

- a) the cDNA insert contained in the plasmid deposited under ATCC accession number 75127 or  
b) a cDNA molecule which hybridizes with the complement of the coding sequence of the cDNA insert of (a), and

wherein the polypeptide is administered to the mammal in sufficient quantity to alter the level of TGF- $\beta$  binding to endogenous TGF- $\beta$  type II receptors, type III receptors, or both.

40. A method of modulating the effects of TGF- $\beta$  in a mammal, comprising administering to the mammal a polypeptide comprising a TGF- $\beta$  binding fragment of the amino acid sequence of a mammalian TGF- $\beta$  type III receptor protein, wherein the mammalian receptor protein has an amino acid sequence selected from the group consisting of:

- a) the amino acid sequence of the TGF- $\beta$  type III receptor protein of SEQ ID NO: 6 or  
b) the amino acid sequence encoded by a mammalian DNA which hybridizes to the complement of SEQ ID NO: 5 under high stringency conditions,

wherein the polypeptide specifically binds to TGF- $\beta$  under conditions appropriate for binding of the TGF- $\beta$  type III receptor to TGF- $\beta$ ;

and wherein the polypeptide is administered to the mammal in sufficient quantity to alter the level of TGF- $\beta$  binding to endogenous TGF- $\beta$  type II receptors, type III receptors, or both.

41. A method of modulating the effects of TGF- $\beta$  in a mammal, comprising administering to the mammal a polypeptide comprising a TGF- $\beta$  binding fragment of the amino acid sequence of a mammalian TGF- $\beta$  type III receptor protein, wherein the mammalian receptor protein has an amino acid sequence encoded by;
- a) the cDNA insert contained in the plasmid deposited under ATCC accession number 75127 or
  - b) a cDNA molecule which hybridizes with the complement of the coding sequence of the cDNA insert of (a), and
- wherein the polypeptide specifically binds to TGF- $\beta$  under conditions appropriate for binding of the TGF- $\beta$  type III receptor to TGF- $\beta$ ; and wherein the polypeptide is administered to the mammal in sufficient quantity to alter the level of TGF- $\beta$  binding to endogenous TGF- $\beta$  type II receptors, type III receptors, or both.
42. A method according to Claim 38, wherein the mammalian TGF- $\beta$  type III receptor protein has the amino acid sequence set forth in SEQ ID NO: 6.
43. A method according to Claim 39, wherein the mammalian TGF- $\beta$  type III receptor protein has the amino acid sequence encoded by the cDNA insert contained in the plasmid deposited under ATCC accession number 75127.
44. A method according to Claim 40, wherein the mammalian TGF- $\beta$  type III receptor protein has the amino acid sequence set forth in SEQ ID NO: 6.
45. A method according to Claim 41, wherein the mammalian TGF- $\beta$  type III receptor protein has the amino acid sequence encoded by the cDNA insert contained in the plasmid deposited under ATCC accession number 75127.---

REMARKS

The amendment to the specification has been made to include a Related Applications section and to correct an error in the specification. In addition, new Claims 31-45 have been added to more particularly claim the present invention. If the Examiner feels that a telephone conference would expedite prosecution of this case, the Examiner is invited to call the undersigned at (781) 861-6240.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By Anne J. Collins  
Anne J. Collins  
Registration No. 40,564  
Telephone (781) 861-6240  
Facsimile (781) 861-9540

Lexington, Massachusetts 02421-4799

Dated: *October 30, 1998*

-1-

TGF- $\beta$  TYPE RECEPTOR cDNAs ENCODED PRODUCTS  
AND USES THEREFOR

Description

Funding

5 Work described herein was funded by National Cancer  
Institute Grant No. R35-CA39826; National Heart, Lung and  
Blood Institute Centers of Excellence Grant HL-41484; the  
Damon Runyon-Walter Winchell Cancer Research Fund;  
National Institutes of Health predoctoral training grant  
10 number T 32 BM07287-16; and the American Cancer Society.  
The United States government has certain rights in the  
invention.

Background

Transforming growth factor-beta (TGF- $\beta$ ) is a member  
15 of a family of structurally related cytokines that elicit  
a variety of responses, including growth, differentia-  
tion, and morphogenesis, in many different cell types.  
(Roberts, A.B. and M.B. Sporn, In: Peptide Growth  
Factors and Their Receptors, Springer-Verlag, Heidelberg,  
20 pp. 421-472 (1990); Massague, J., Annu. Rev. Cell. Biol.  
6:597-641 (1990)) In vertebrates at least five different  
forms of TGF- $\beta$ , termed TGF- $\beta$ 1 to TGF- $\beta$ 5, have been  
identified; they all share a high degree (60%-80%) of  
amino-acid sequence identity. While TGF- $\beta$ 1 was initially  
25 characterized by its ability to induce anchorage-  
independent growth of normal rat kidney cells, its  
effects on most cell types are anti-mitogenic. (Altschul,  
S.F. et al., J. Mol. Biol. 215:403-410 (1990); Andres,  
J.L. et al., J. Cell. Biol. 109:3137-3145 (1989)) It is

strongly growth-inhibitory for many types of cells, including both normal and transformed epithelial, endothelial, fibroblast, neuronal, lymphoid, and hematopoietic cells. In addition, TGF- $\beta$  plays a central role in regulating the formation of extracellular matrix and cell-matrix adhesion processes.

In spite of its widespread effects on cell phenotype and physiology, little is known about the biochemical mechanisms that enable TGF- $\beta$  family members to elicit these varied responses. Three distinct high-affinity cell-surface TGF- $\beta$ -binding proteins, termed type I, II and III, have been identified by incubating cells with radiolabelled TGF- $\beta$ 1, cross-linking bound TGF- $\beta$ 1 to cell surface molecules, and analyzing the labelled complexes by polyacrylamide gel electrophoresis. (Massague, J. and B. Like, J. Biol. Chem. 260:2636-2645 (1985); Cheifetz, S. et al. J. Biol. Chem. 261:9972-9978 (1986).) The binding constants are about 5-50pM for the type I and II receptor and 30-300 pM for the type III receptor. (Boyd, F.T. and J. Massague, J. Biol. Chem. 264:2272-2278 (1989))

The type I and II receptors, of estimated 53 and 70-100 kilodaltons mass respectively, are N-glycosylated transmembrane proteins that are similar in many respects. Each of these receptors has a distinct affinity for each member of the TGF- $\beta$  family of ligands. (Boyd, F.T. and J. Massague, J. Biol. Chem. 264:2272-2278 (1989)) In contrast, the type III receptor shows comparable affinities for all TGF- $\beta$  isotypes; the type III receptor is the most abundant cell-surface receptor for TGF- $\beta$  in many cell lines (upwards of 200,000 per cell), and is an integral membrane proteoglycan. It is heavily modified

by glycosaminoglycan (GAG) groups, and migrates hetero-  
geneously upon gel electrophoresis as proteins of 280 to  
330 kilodaltons. When deglycosylated with heparitinase  
and chondroitinase, the protein core migrates as a  
5 100-110 kilodalton protein. The TGF- $\beta$  binding site  
resides in this protein core, as non-glycosylated forms  
of this receptor that are produced in cell mutants  
defective in GAG synthesis are capable of ligand binding  
with affinities comparable to those of the natural  
10 receptor. (Cheifetz, S. and J. Massague, J. Biol. Chem.,  
264:12025-12028 (1989) A variant form of type III  
receptor is secreted by some types of cells as a soluble  
molecule that apparently lacks a membrane anchor. This  
soluble species is found in low amounts in serum and in  
15 extracellular matrix.

The type III receptor, also called betaglycan, has a  
biological function distinct from that of the type I and  
II receptors. Some mutant mink lung epithelial cell  
(Mv1Lu) selected for loss of TGF- $\beta$  responsiveness no  
20 longer express type I receptors; others, similarly  
selected, lose expression of both the type I and II  
receptors. However, all these variants continue to  
express the type III receptor. (Boyd, F.T. and J.  
Massague, J. Biol. Chem. 264:2272-2278 (1989); Laiho, M.  
25 et al., J. Biol. Chem. 265:18518-18524 (1990)) This has  
led to the proposal that types I and II receptors are  
signal-transducing molecules while the type III receptor,  
may subserve some other function, such as in concen-  
trating ligand before presentation to the bona fide  
30 signal-transducing receptors. The secreted form of type  
III receptor, on the other hand, may act as a reservoir  
or clearance system for bioactive TGF- $\beta$ .

Additional information about each of these TGF- $\beta$  receptor types would enhance our understanding of their roles and make it possible, if desired, to alter their functions.

5     Summary of the Invention

          The present invention relates to isolation, sequencing and characterization of DNA encoding the TGF- $\beta$  type III receptor of mammalian origin and DNA encoding the TGF- $\beta$  type II receptor of mammalian origin. It also  
10     relates to the encoded TGF- $\beta$  type III and type II receptors, as well as to the soluble form of each; uses of the receptor-encoding genes and of the receptors themselves; antibodies specific for TGF- $\beta$  type III receptor and antibodies specific for TGF- $\beta$  type II receptor. In  
15     particular, it relates to DNA encoding the TGF- $\beta$  type III receptor of rat and human origin, DNA encoding the TGF- $\beta$  type II receptor of human origin and homologues of each.

          The TGF- $\beta$  receptor-encoding DNA of the present invention can be used to identify equivalent TGF- $\beta$   
20     receptor type III and type II genes from other sources, using, for example, known hybridization-based methods or the polymerase chain reaction. The type III receptor gene, the type II receptor gene or their respective encoded products can be used to alter the effects of  
25     TGF- $\beta$  (e.g., by altering receptivity of cells to TGF- $\beta$  or interfering with binding of TGF- $\beta$  to its receptor), such as its effects on cell proliferation or growth, cell adhesion and cell phenotype. For example, the TGF- $\beta$  receptor type III gene, the TGF- $\beta$  receptor type II gene,  
30     or a truncated gene which encodes less than the entire receptor (e.g., soluble TGF- $\beta$  type III receptor, soluble

TGF- $\beta$  type II receptor or the TGF- $\beta$  type III or type II binding site) can be administered to an individual in whom TGF- $\beta$  effects are to be altered. Alternatively, the TGF- $\beta$  type III receptor, the TGF- $\beta$  type II receptor, a  
5 soluble form thereof (i.e., a form lacking the membrane anchor) or an active binding site of the TGF- $\beta$  type III or the type II receptor can be administered to an individual to alter the effects of TGF- $\beta$ .

Because of the many roles TGF- $\beta$  has in the body,  
10 availability of the TGF- $\beta$  receptors described herein makes it possible to further assess TGF- $\beta$  function and to alter (enhance or diminish) its effects.

#### Brief Description of the Drawings

Figure 1 is the DNA sequence and the translated  
15 amino acid sequence of type III TGF- $\beta$ 1 receptor cDNA clone R3-OFF (full insert size 6 kb), in which the open reading frame with flanking sequences of the clone are shown. The transmembrane domain is indicated by a single underline. Peptide sequences from purified type III  
20 receptor, mentioned in text, that correspond to the derived sequence, are in italics and underlined.

Potential N-linked glycosylation sites are indicated by #, and extracellular cysteines by &. A consensus protein kinase C phosphorylation site is indicated by \$. The  
25 last non-vectorencoded amino acid of Clone R3-OF (2.9 kb) is indicated by @. Consensus proteoglycan attachment site is indicated by +++. Other potential glycosaminoglycan attachment sites are indicated by +.

The upstream in-frame stop codon (-42 to -44) is

30 indicated by a wavy line. Signal peptide cleavage site



predicted by vonHeijne's algorithm (von Heijne, G., Nucl. Acid. Res. 14:4683-4690 (1986) is indicated by an arrow.

Figure 2 is the nucleotide sequence of the full-length type II TGF- $\beta$  receptor cDNA clone 3FF isolated from a human HepG2 cell cDNA library (full insert size 5 kb). The cDNA has an open reading frame encoding a 572 amino acid residue protein.

Figure 3 is the amino acid sequence of the full-length type II TGF- $\beta$  receptor.

#### 10 Detailed Description of the Invention

The subject invention is based on the isolation and sequencing of DNA of vertebrate, particularly mammalian, origin which encodes TGF- $\beta$  type III receptor and DNA of mammalian origin which encodes TGF- $\beta$  type II receptor, expression of the encoded products and characterization of the expressed products. As described, a full-length cDNA which encodes TGF- $\beta$  receptor type III has been isolated from a cDNA library constructed from a rat vascular smooth muscle cell line and a full-length cDNA which encodes TGF- $\beta$  type II receptor has been isolated from a human cDNA library. The human homologue of the type III gene has also been cloned. A deposit of human TGF- $\beta$  type III cDNA in the plasmid pBSK has been made under the terms of the Budapest Treaty at the American Type Culture Collection (10/21/91) under Accession Number 75127. All restrictions upon the availability of the deposited material will be irrevocably removed upon granting of a U.S. patent based on the subject application.

Isolation and Characterization of TGF- $\beta$  Type III  
Receptor

As described herein, two separate strategies were pursued for the isolation of the TGF- $\beta$  type III receptor cDNA. In one approach, monoclonal antibodies were generated against the type III receptor protein and used to purify the receptor, which was then subjected to microsequencing. (See Example 1) Microsequencing of several peptides resulting from partial proteolysis of the purified receptor produced four oligopeptide sequences, which were used to construct degenerate oligonucleotides. The degenerate oligonucleotides were used either as primers in a cloning strategy using the polymerase chain reaction (PCR) or as probes in screening cDNA libraries. Although this strategy did not prove to be productive, the oligopeptide sequences were useful in verifying the identity of the receptor clones isolated by the second strategy.

In the second approach to isolating TGF- $\beta$  receptor-encoding clones, an expression cloning strategy was used in COS cells; direct visualization of receptor positive cells was used to isolate receptor cDNAs. (See Example 2) In this approach, a cDNA library was constructed from A-10 cells, a rat vascular smooth muscle cell line which expresses all three TGF- $\beta$  receptors (type I, II and III). COS cells transfected with cDNA components of this library in a vector carrying the cytomegalovirus (CMV) transcriptional promoter and the SV40 origin of replication were screened to identify cells expressing substantially higher than normal levels of TGF- $\beta$  receptor. One transfectant expressing such high levels of a TGF- $\beta$

binding protein was identified and the original pool of expression constructs from which it was derived was split into subpools, which were subjected to a second round of screening. Two further rounds of sib-selection resulted in isolation of one cDNA clone (R3-OF) with a 2.9 kb insert which induced high levels of TGF- $\beta$ -binding proteins in approximately 10% of cells into which it was introduced. The specificity of the TGF- $\beta$  binding was validated by showing that addition of a 200-fold excess unlabeled competitor TGF- $\beta$ 1 strongly reduced binding of <sup>125</sup>I-TGF- $\beta$  to transfected cells.

The R3-OF cDNA encoded an open reading frame of 817 amino acid residues, but did not contain a stop codon. R3-OF was used as a probe to isolate a full-length cDNA from a rat 208F library. The resulting clone, R3-OFF, is 6kb in length and encodes a protein of 853 amino acids, which is colinear with clone R3-OF. The nucleotide sequence of R3-OFF is shown in Figure 1, along with the translated amino acid sequence.

Characterization of the receptor encoded by R3-OFF was carried out, as described in Example 3. Results showed three distinct TGF- $\beta$  binding protein species of TGF- $\beta$  on the surface of mock-transfected COS cells, which is in accord with results reported by others. (Massague, J. et al., Ann. NY Acad. Sci. 593:59-72 (1990)). These included the two lower molecular weight type I and II receptors (65 and 85 kD) and the higher molecular weight type III proteoglycan, which migrates as a diffuse band of 280-330 kd. Enzymatic removal of the proteoglycan yielded a core protein of approximately 100 kd. Binding

to all three receptor types is specific in that it was competed by 200-fold excess of unlabeled TGF- $\beta$ 1.

Transfecting the isolated cDNA caused a two-fold increase in expression of the type III receptor. When a cell lysate derived from COS cells transfected with clone R3-OFF was treated with deglycosylating enzymes, the heterogeneous 280-330 kd band was converted to a protein core which co-migrates with the type III protein core seen in parental A10 cells. Importantly, the recombinant protein core migrated differently from the endogenous COS cell type III protein core.

These observations were confirmed and extended using stably transfected cells expressing the type III cDNA. L6 rat skeleton muscle myoblasts do not express any detectable type III mRNA and no endogeneous surface type III receptor (Massague *et al.*, 1986; Segarini *et al.*, 1989). These cells were transfected with the isolated cDNA in the vector pcDNA-neo. Cell clones stably expressing this clone in both the forward and reverse orientations with respect to the CMV promoter were isolated and analyzed by ligand binding assay.

Introduction of either the full-length clone R3-OFF or the partial clone R3-OF in the forward orientation resulted in expression of type III receptor. L6 cells transfected with the cDNA clones in the reverse orientation did not express this protein. Importantly, the apparent size of the protein core of the type III receptor in cells transformed with the R3-OF clone is smaller than that from R3-OFF transformed cells, consistent with the difference in the sizes of the

protein cores predicted from their nucleic acid sequences.

Surprisingly, binding of radio-labeled ligand to the type II receptor was increased by 2.5 fold in cells expressing the type III cDNA. Binding to the type I receptor was unchanged. This apparently specific up-regulation of ligand-binding to the type II receptor was evident in all of the 15 stably transfected L6 cell lines analyzed to date. Furthermore, this effect seems to be mediated equally well by the full-length clone or a truncated clone (R3-OF) that lacks the cytoplasmic domain of TGF- $\beta$  type III receptor was expressed.

Expression of type III receptor mRNA was assessed by Northern blot analysis and RNA blot analysis. Northern gel analysis showed that the type III receptor mRNA is expressed as a single 6 kb message in several rat tissues. RNA dot blot analysis of several different tissue culture cell lines was also carried out. Cells of mouse origin (MEL and YH16) appear to express a smaller (~5.5 kb) message for the type III mRNA than those of pig, rat and human origin. In all of these cells, expression or absence of the type III mRNA is consistent with the expression or absence of detectable cell surface type III receptors, with the notable exception of the retinoblastoma cell lines (Y79, Weri-1, Weri-24, and Weri-27). These cells lack detectable surface expression of type III receptor, which confirms an earlier report. (Kimchi, A. et al., Science 240:196-198 (1988)). It is striking that the type III receptor mRNA is expressed in these cells at a level comparable to that of other cells that do indeed express type III receptor proteins at

readily detectable levels. It appears that TGF- $\beta$  receptor III expression, which is substantial in normal retinoblasts (AD12), has been down-regulated in these retinoblastoma tumor cells, perhaps through post-transcriptional mechanisms.

The nucleotide sequence full reading frame along with flanking sequences of the full-length cDNA clone R3-OFF was determined and is presented in Figure 1. The reading frame encodes a protein of 853 amino acid residues, which is compatible with the 100 kD size observed for the fully deglycosylated TGF- $\beta$ 1 type III receptor. The identity of the receptor as TGF- $\beta$  type III was verified by searching for segments of the putative transcription product which included the peptide sequences determined by microsequencing of the isolated type III receptor. (See Example 1) As indicated in Figure 1, two segments of derived protein (underlined and italicized, residues 378-388 and 427-434) precisely match with the amino acid sequences of two peptides (I and III) determined from direct biochemical analysis of the purified type III receptor.

Further analysis showed that TGF- $\beta$  type III binding protein has an unusual structure for a cytokine receptor. Hydropathy analysis indicates that the protein includes a N-terminal signal sequence, followed by a long, hydrophilic N-terminal region. A 27 residue region of strong hydrophobicity (underlined in Figure 1, residues 786-812) toward the C-terminus represents the single putative transmembrane domain. This suggests that nearly all of the receptor which is an N-terminal extracellular domain is anchored to the plasma membrane near its C-terminus.

A relatively small C-terminal tail of 41 residues represents the cytoplasmic domain.

Analysis of related sequences provides few clues to function of TGF- $\beta$  type III protein. Only one other gene described to date, a glycoprotein expressed in high quantities by endothelial cells and termed endoglin, contains a related amino acid sequence. The most homologous region: between the sequences of the type III receptor and endoglin (74%) falls primarily in the putative transmembrane and cytoplasmic domains. Similar to the general structure of type III receptor, endoglin is a glycoprotein which contains a large hydrophilic N-terminal domain which is presumably extracellular, followed by a putative transmembrane domain and a short cytoplasmic tail of 47 amino acid residues. The biological role of endoglin is still unclear at present, although it has been suggested that it may involved in cell-cell recognition through interactions of an "RGD" sequence on its ectodomain with other adhesion molecules. Unlike the TGF- $\beta$  type III receptor, endoglin does not carry GAG groups.

#### Isolation of TGF- $\beta$ Type II Receptor

The cDNA encoding the type II TGF- $\beta$  receptor was also isolated, using expression cloning in COS cells. A full-length cDNA (designated clone 3FF) was isolated by high stringency hybridization from a human HepG2 cell cDNA library. (See Example 6) Analysis showed that the corresponding message is a 5 kb message which is expressed in different cell lines and tissues. Sequence analysis indicated that the cDNA has an open reading frame encoding a core 572 amino acid residue protein. The nucleotide sequence of the full-length type II TGF- $\beta$

receptor cDNA clone 3FF is shown in Figure 2; the amino acid sequence is represented in Figure 3.

The 572 amino acid residue protein has a single putative transmembrane domain, several consensus glycosylation sites, and a putative intracellular serine/threonine kinase domain. The predicted size of the encoded protein core is ~60 kd, which is too large for a type I TGF- $\beta$  receptor. Instead, crosslinking experiments using iodinated TGF- $\beta$  and COS cells transiently transfected with clone 3FF shows over-expression of a protein approximately 70-80 kd which corresponds to the size of type II TGF- $\beta$  receptors. Thus, clone 3FF encodes a protein that specifically binds TGF- $\beta$  and has an expressed protein size of 70-80 kd, both characteristic of the type II TGF- $\beta$  receptor.

#### Uses of the Cloned TGF- $\beta$ Receptors and Related Products

For the first time, as a result of the work described herein, DNAs encoding two of the three high affinity cell-surface TGF- $\beta$  receptors have been isolated, their sequences and expression patterns determined and the encoded proteins characterized. Expression of the TGF- $\beta$  type III receptor in cells which do not normally express the receptor, followed by ligand binding assay, verified that the cloned type III receptor-encoding DNA (i.e., either the full-length clone R3-OFF or the partial clone R3-OF) encoded the receptor. In addition, the work described herein resulted in the surprising finding that binding of TGF- $\beta$  to type II receptors in cells expressing the type III DNA was increased by 2.5 fold.

Additional insight into the role of the TGF- $\beta$  type III receptor and its interaction with TGF- $\beta$  type II



receptor is a result of the work described. For example, the role of TGF- $\beta$  type III receptor is unclear, but it has been proposed that it serves a most unusual function of attracting and concentrating TGF- $\beta$ s for eventual transfer to closely situated signal-transducing receptors. While most cytokines bind to a single cell surface receptor, members of the TGF- $\beta$  family bind with greater or lesser affinity to three distinct cell surface proteins. This has raised the question of why these three receptors are displayed by most cell types and whether they subserve distinct functions. Evidence obtained to date suggests that the type III receptor may perform functions quite different from those of types I and II. Thus, type III is substantially modified by GAGs while types I and II appear to carry primarily the N-linked (and perhaps O-linked) sidechains that are characteristic of most growth factor receptors. In addition, variant cells that have been selected for their ability to resist TGF- $\beta$ -induced growth inhibition show the absence of Type I or Type II receptors while continuing to display Type III receptors. Together, these data have caused some to propose that the Type I and II receptors represent bona fide signal-transducing receptors while the type III receptor, described here, plays another distinct role in the cell.

It remains possible that the type III receptor serves a most unusual function of attracting and concentrating TGF- $\beta$ s on the cell surface for eventual transfer to closely situated signal-transducing receptors. Such a function would be unprecedented for a proteinaceous receptor, although heparin sulfate has been

shown to activate basic FGF by binding to this growth factor prior to FGF association with its receptor (Yayon, A. et al., Cell 64:841-848 (1991)) Parenthetically, since the type III receptor also contains large

5 quantities of heparan sulfate side-chains, it may also bind and present basic FGF to its receptor.

Evidence that is consistent with the role for the type III receptor comes from the work with L6 rat myoblast cells which is described herein. As described

10 above, in L6 cells overexpressing type III receptor, the binding of radiolabelled TGF- $\beta$  to the type II receptor is increased several fold when compared with that seen with parental cells. Further assessment of TGF- $\beta$  type III function and interaction with type II and type I

15 receptors will be needed to answer these questions and can be carried out using the materials and methods described here.

TGF- $\beta$  receptors, both type III and type II, can be identified in other species, using all or a portion of

20 the DNA encoding the receptor to be identified as a probe and methods described herein. For example, all or a portion of the DNA sequence encoding TGF- $\beta$  type III receptor (shown in Figure 1) or all or a portion of the DNA sequence encoding TGF- $\beta$  type II receptor (shown in

25 Figure 2) can be used to identify equivalent sequences in other animals. Stringency conditions used can be varied, as needed, to identify equivalent sequences in other species. Once a putative TGF- $\beta$  receptor type III or type II-encoding sequence has been identified, whether it

30 encodes the respective receptor type can be determined using known methods, such as described herein for

verification that the cDNA insert of full-length clone R3-OFF and the cDNA insert of partial clone R3-OF encode the type III receptor. For example, DNA isolated in this manner can be expressed in an appropriate host cell which does not express the receptor mRNA or the surface receptor (e.g., L6 rat skeleton muscle myoblasts) and analyzed by ligand binding (TGF- $\beta$  binding) assay, as described herein.

Also as a result of the work described herein, antibodies (polyclonal or monoclonal) specific for the cloned TGF- $\beta$  type III or the clones TGF- $\beta$  type II receptor can be produced, using known methods. Such antibodies and host cells (e.g., hybridoma cells) producing the antibodies are also the subject of the present invention. Antibodies specific for the cloned TGF- $\beta$  receptor can be used to identify host cells expressing isolated DNA thought to encode a TGF- $\beta$  receptor. In addition, antibodies can be used to block or inhibit TGF- $\beta$  activity. For example, antibodies specific for the cloned TGF- $\beta$  type III receptor can be used to block binding of TGF- $\beta$  to the receptor. They can be administered to an individual for whom reduction of TGF- $\beta$  binding is desirable, such as in some fibrotic disease (e.g., of skin, kidney and lung).

DNA and RNA encoding TGF- $\beta$  type III receptor and DNA and RNA encoding TGF- $\beta$  type II receptor are now available. As used herein, the term DNA or RNA encoding the respective TGF- $\beta$  receptor includes any oligodeoxynucleotide or oligodeoxyribonucleotide sequence which, upon expression, results in production of a TGF- $\beta$  receptor having the functional characteristics of the

TGF- $\beta$  receptor. That is, the present invention includes DNA and RNA which, upon expression in an appropriate host cell, produces a TGF- $\beta$  type III receptor which has an affinity for TGF- $\beta$  similar to that of the TGF- $\beta$  type III receptor on naturally occurring cell surfaces (e.g., it shows comparable affinities for all TGF- $\beta$  isotypes). Similarly, the present invention includes DNA and RNA which, upon expression in an appropriate host cell, produces a TGF- $\beta$  type II receptor which has an affinity for TGF- $\beta$  similar to that of TGF- $\beta$  type II receptor on naturally occurring cell surfaces (e.g., it has a distinctive affinity for each member of the TGF- $\beta$  family of ligands similar to that of the naturally occurring TGF- $\beta$  type II receptor). The DNA or RNA can be produced in an appropriate host cell or can be produced synthetically (e.g., by an amplification technique such as PCR) or chemically.

The present invention also includes the isolated TGF- $\beta$  type III receptor encoded by the nucleotide sequence of full-length R3-OFF, the isolated TGF- $\beta$  type III receptor encoded by the nucleotide sequence of partial clone R3-OF, the isolated TGF- $\beta$  type II receptor encoded by the nucleotide sequence of full-length clone 3FF and TGF- $\beta$  type III and type II receptors which bind TGF- $\beta$  isotypes with substantially the same affinity. The isolated TGF- $\beta$  type III and type II receptors can be produced by recombinant techniques, as described herein, or can be isolated from sources in which they occur naturally or synthesized chemically. As used herein, the terms cloned TGF- $\beta$  type III and cloned TGF- $\beta$  type II receptors include the respective receptors identified as

described herein, and TGF- $\beta$  type III and type II receptors (e.g., from other species) which exhibit substantially the same affinity for the TGF- $\beta$  isotypes as the respective receptors.

5       As described previously, cells in which the cloned TGF- $\beta$  type III receptor is expressed bind TGF- $\beta$  in essentially the same manner as do cells on which the type III receptor occurs naturally. Further analysis of ligand interactions with the cloned TGF- $\beta$  type III  
10 receptor, based upon site-directed mutagenesis of both TGF- $\beta$  and the receptor, can be carried out to identify residues important for binding. For example, DNA having the sequence of Figure 1 can be altered by adding, deleting or substituting at least one nucleotide, in  
15 order to produce a modified DNA sequence which encodes a modified cloned TGF- $\beta$  type III receptor. The functional characteristics of the modified receptor (e.g., its TGF- $\beta$ -binding ability and association of the binding with effects normally resulting from binding) can be assessed,  
20 using the methods described herein. Modification of the cloned TGF- $\beta$  type III receptor can be carried out to produce, for example, a form of the TGF- $\beta$  type III receptor, referred to herein as soluble TGF- $\beta$  receptor, which is not membrane bound and retains the ability to  
25 bind the TGF- $\beta$  isotypes with an affinity substantially the same as the naturally-occurring receptor. Such a TGF- $\beta$  type III receptor could be produced, using known genetic engineering or synthetic techniques; it could include none of the transmembrane region present in the  
30 naturally-occurring TGF- $\beta$  type III receptor or only a small portion of that region (i.e., small enough not to

interfere with its soluble nature). For example, it can include amino acids 1 through 785 of the TGF- $\beta$  type III sequence of Figure 1 or a portion of that sequence sufficient to retain TGF- $\beta$  binding ability (e.g., amino acids 24-785, which does not include the signal peptide cleavage site present in the first 23 amino acids). A soluble TGF- $\beta$  type II receptor (e.g., one which does not include the transmembrane and cytoplasmic domains) can also be produced. For example, it can include amino acids 1 through 166, inclusive, of Figure 3 or a sufficient portion thereof to retain TGF- $\beta$  binding ability substantially the same as that of TGF- $\beta$  type II receptor.

The TGF- $\beta$  type III receptor and/or type II receptor can be used for therapeutic purposes. As described above, the TGF- $\beta$  family of proteins mediate a wide variety of cellular activities, including regulation of cell growth, regulation of cell differentiation and control of cell metabolism. TGF- $\beta$  may be essential to cell function and most cells synthesize TGF- $\beta$  and have TGF- $\beta$  cell surface receptors. Depending on cell type and environment, the effects of TGF- $\beta$  vary: proliferation can be stimulated or inhibited, differentiation can be induced or interrupted and cell functions can be stimulated or suppressed. TGF- $\beta$  is present from embryonic stages through adult life and, thus, can affect these key processes throughout life. The similarities of a particular TGF- $\beta$  (e.g., TGF- $\beta$ 1) across species and from cell to cell are considerable. For example, the amino acid sequence of a particular TGF- $\beta$  and the nucleotide sequence of the gene which encodes it regardless of

source, are essentially identical across species. This further suggests that TGF- $\beta$  has a critical role in essential processes.

Specifically, TGF- $\beta$  has been shown to have anti-inflammatory and immune suppression capabilities, to play an important role in bone formation (by increasing osteoblast activity), inhibit cancer cell proliferation in culture, and control proliferation of glandular cells of the prostate. As a result, it has potential therapeutic applications in altering certain immune system responses (and possibly in modifying immune-mediated diseases); in treating systemic bone disease (e.g., osteoporosis) and conditions in which bone growth is to be enhanced (e.g., repair of broken bones) and in controlling growth and metastasis of cancer cells. In addition, TGF- $\beta$  appears to play a role in determining whether some cell types undergo or do not undergo mitosis. In this respect, TGF- $\beta$  may play an important role in tissue repair. Some diseases or conditions appear to involve low production or chronic overproduction of TGF- $\beta$ . (For example, results of animal studies suggest that there is a correlation between the over production of TGF- $\beta$  and diseases characterized by fibrosis in the lung, kidney, liver or in viral mediated immune expression.)

Clearly, TGF- $\beta$  has key roles in body processes and numerous related potential clinical or therapeutic applications in wound healing, cancer, immune therapy and bone therapy. Availability of TGF- $\beta$  receptor genes, the encoded products and methods of using them in vitro and in vivo provides an additional ability to control or regulate TGF- $\beta$  activity and effect in the body. For

example, the TGF- $\beta$  type II or type III receptor encoded by the type II or the type III receptor genes of the subject invention can be used, as appropriate, to alter the effects of TGF- $\beta$  (e.g., to enhance the effect of TGF- $\beta$  in the body or to inhibit or reduce (totally or partially) its effects). It is also possible to administer to an individual in whom TGF- $\beta$  bound to TGF- $\beta$  type III receptor, such as soluble TGF- $\beta$  type III receptor. The present invention provides both a TGF- $\beta$  agonist and a TGF- $\beta$  antagonist. For these purposes, DNA gene encoding the entire TGF- $\beta$  type II or type III receptor, the encoded type II or type III receptor or a soluble form of either receptor can be used. Alternatively, antibodies or other ligands designed based upon these sequences or specific for them can be used for this purpose.

Knowledge of the amino acid sequences of TGF- $\beta$  type III and type II receptors makes it possible to better understand their structure and to design compounds which interfere with binding of the receptor with TGF- $\beta$ . It makes possible identification of existing compounds and design of new compounds which are type III and/or type II receptor antagonists.

Cells expressing the type III and/or type II receptors of the present invention can be used to screen compounds for their ability to interfere with (block totally or partially) TGF binding to the receptors. For example, cells which do not express TGF- $\beta$  type III receptor (e.g., L6 rat skeleton muscle myoblasts) but have been modified to do so by incorporation of the type III cDNA in an appropriate vector can be used for this



purpose. A compound to be assessed is added, for example, to tissue culture dishes containing type III expressing cells, along with labeled TGF- $\beta$ . As a control, the same concentration of labeled TGF- $\beta$  is added to tissue culture dishes containing the same type of cells. After sufficient time for binding of TGF- $\beta$  to the receptor to occur, binding of labeled TGF- $\beta$  to the cells is assessed, using known methods (e.g., by means of a gamma counter) and the extent to which it occurred in the presence and in the absence of the compound to be assessed is determined. Comparison of the two values show whether the test compound blocked TGF- $\beta$  binding to the receptor (i.e., less binding in the presence of the compound than in its absence is evidence that the test compound has blocked binding of TGF- $\beta$  to the TGF- $\beta$  type III receptor).

Alternatively, a cell line expressing the TGF- $\beta$  receptor or cells expressing microinjected TGF- $\beta$  receptor RNA, can be used to assess compounds for their ability to block TGF- $\beta$  binding to the receptor. In this embodiment, a compound to be assessed is added to tissue culture dishes containing the cell line cells expressing microinjected TGF- $\beta$  receptor RNA, along with TGF- $\beta$ . As a control, TGF- $\beta$  alone is added to the same type of cells expressing microinjected endothelin receptor RNA. After sufficient time for binding of TGF- $\beta$  to the receptor to occur, the extent to which binding occurred is measured, both in the presence and in the absence of the compound to be assessed. Comparison of the two values shows whether the compound blocked TGF- $\beta$  binding to the receptor. The TGF- $\beta$  type III and type II receptors can

also be used to identify TGF- $\beta$ -like substances, to purify TGF- $\beta$  and to identify TGF- $\beta$  regions which are responsible for binding to the respective receptors. For example, the type III receptor can be used in an affinity-based method to identify substances which bind the receptor in a manner similar to TGF- $\beta$ .

The invention will now be illustrated by the following examples, which are not intended to be limiting in any way.

10

#### EXAMPLES

Materials and methods used in Examples 1-5 are described below.

##### Materials

The following is a description of materials used in the work described herein.

Recombinant human TGF- $\beta$ 1 was provided by Rik Derynck of Genentech. COS-M6 cells were provided by Brian Seed of the Massachusetts General Hospital and Alejandro Aruffo of Bristol-Myers-Squibb. Heparitinase was provided by Tetsuhito Kojima and Robert Rosenberg of MIT. LLC-PK<sub>1</sub> cells were a gift of Dennis Ausiello of the Massachusetts General Hospital. YH-16 cell were a gift of Edward Yeh of the Massachusetts General Hospital. 3-4 cells were a gift of Eugene Kaji of the Whitehead Institute for Biomedical Research. All other cell lines were purchased from ATCC and grown as specified by the supplier, except as noted.

Expression Cloning

Construction of cDNA Library and Generation of  
Plasmid Pools

10µg polyadenylated mRNA was prepared from A10 cells  
5 by the proteinase-K/SDS method (Gonda et al., Molec.  
Cell. Biol. 2:617-624 (1982)). Double stranded cDNA was  
synthesized and linkered to nonpalindromic BstX1 adaptors  
as described by Seed, B. and A. Aruffo, Proc. Natl. Acad.  
Sci. USA 84:3365-3369 (1987). Acaptured cDNA was size-  
10 fractionated on a 5 to 20% potassium acetate gradient,  
and inserts greater than 1 kb were ligated to the plasmid  
vector pcDNA-1, and electroporated in the E. coli  
MC1061/P3, yielding a primary library with a titer of  
>10<sup>7</sup> recombinants. A portion of the cDNA was plated as  
15 pools of ~1x10<sup>4</sup> recombinant bacteria colonies grown on 15  
cm petri dishes with Luria-broth agar containing 7.5  
mg/ml tetracycline and 12.5 mg/ml ampicillin. Cells were  
scraped off the plates in 10 mls of Luria-broth, and  
glycerol stocks of pooled bacteria were stored at -70°C.  
20 The remaining bacteria was used to purify plasmid DNA  
using the alkaline lysis mini-prep method (Sambrook, J.  
et al., Molecular Cloning: A Laboratory Manual, 2d Ed.  
(Cold Spring Harbor, NY, Cold Spring Harbor Laboratory  
Press (1989)).

COS Cell Transfections and Binding Assay

25 Plasmid pools (each representing ~1x10<sup>4</sup> clones) were  
transfected into COS-M6 (subclone of COS-7 cells) by the  
DEAE-dextran/chloroquine method described by Seed, B. and  
A. Aruffo, Proc. Natl. Acad. Sci. USA 84:3365-3369  
30 (1987). Forty-eight hours after transfection, cells were

incubated with 50 pM<sup>125</sup>I-TGF- $\beta$ 1 (100 to 200 Ci/mmol) for 4 hours at 4°C), autoradiographic analysis of transfected cells was performed using NT-B2 photographic emulsion (Kodak) essentially as described (Gearing, D.P. et al., EMBO J. 8:3667-3676 (1989)). After development of slides, cells were air-dried and mounted with mounting media and a glass coverslip. Slides were analyzed under an Olympus OM-T1 inverted phase-contrast microscope using a dissection trans-illuminator for darkfield illumination.

#### Subdivision of Positive Pool

Of 86 pools screened, one pool (#13) was identified as positive and a glycerol stock of bacteria corresponding to this pool was titered and 25 pools of 1000 clones were generated and miniprep plasmid from these pools were transfected into COS cells as described above. Several positive pools of 1000 were identified, and one was replated as 25 plates of 100 colonies. A replica was made of this positive plate and harvested. Once a positive pool was identified, individual colonies were picked from the corresponding master plate and grown overnight in 3 ml liquid culture. A 2-dimensional grid representing the 100 clones was generated and a single clone, R3-OF, was isolated.

#### Cloning of R3-OFF

A 208F rat fibroblast library in lambda ZAP II (Stratagene) was screened at high stringency with clone R3-OF insert, and several clones with ~6kb inserts were isolated, one of which is referred to as R3-OFF.

#### DNA Sequencing and Sequence Analysis

Double-stranded DNA was sequenced by the dideoxy chain termination method using Sequenase reagents (United States Biochemicals). Comparison of the sequence to the data bases was performed using BLAST (Altschul, S.F. et al., J. Mol. Biol. 215:403-410 (1990)).

#### Iodination of TGF- $\beta$

TGF- $\beta$ 1 was iodinated using the chloramine-T method as described (Cheifetz, S. and J.L. Andres, J. Biol. Chem. 263:16984-16991 (1988)).

#### Chemical Cross-Linking

Transfected COS cells grown on 10 cm dishes or subconfluent L6 and A-10 cells grown on 3.5 cm dishes were incubated with  $^{125}\text{I}$ -TGF- $\beta$ 1 in binding buffer (Frebs-Ringer buffered with 20 mM Hepes, pH 7.5, 5 mM  $\text{MgSO}_4$ , 0.5% BSA), washed 4 times with ice-cold binding buffer without BSA, and incubated for 15 minutes with binding buffer without BSA containing 60ng/ml disuccinimidyl suberate at 4°C under constant rotation. Crosslinking was terminated by addition of 7% sucrose in binding buffer. Cells were scraped, collected and pelleted by centrifugation, then resuspended in lysis buffer (10 mM Tris, pH 7.4, 1 mM EDTA, pH 8.0, 1% Triton-X 100, 10  $\mu\text{g}/\text{ml}$  of pepstatin, 10 $\mu\text{g}/\text{ml}$  leupeptin, 10  $\mu\text{g}/\text{ml}$  antipain, 100  $\mu\text{g}/\text{m}$ ; benzamidine hydrochloride, 100  $\mu\text{g}/\text{ml}$  soybean trypsin inhibitor, 50  $\mu\text{g}/\text{ml}$  aprotonin, and 1 mM phenylmethylsulfonyl fluoride). Solubilized material was analyzed by 7% SDS-PAGE and subjected to

autoradiographic analysis by exposure to X-AR film  
(Kodak) at -70°C.

#### Enzymatic Digestion

5 Digestion of solubilized TGF-b receptors with  
chondroitinase and heparitinase was performed as  
described (Cheifetz, S. and J.L. Andres, J. Biol. Chem.  
263:16984-16991 (1988); Segarini, P.R. and S.M. Seyedin,  
J. Biol. Chem., 263: 8366-8370 (1988).

#### Generation of Stable Cell Lines

10 L6 myoblasts were split 1:10 into 10 cm dishes and  
transfected the following day by the calcium phosphate  
method (Chen, C. and H. Okayama, Molec. Cell. Biol.  
7:2745-2752 (1987)) with clones R3-OF or R3-OFF in the  
forward and reverse orientations in the vector pcDNA-neo  
15 (InVitrogen). Cells were subjected to selection in the  
presence of G418 (Geneticin, GIBCO) for several weeks  
until individual colonies were visible by the naked eye.  
These clones were isolated and amplified.

#### RNA Blot Analyses

20 Rat tissue polyadenylated mRNA was prepared by the  
lithium chloride/urea method (Auffrey, C. and F. Raugeon,  
Eur. J. Biochemistry 107:303-313 (1980), followed by  
oligo-dT cellulose chromatography (Aviv and Leder, 1972).  
Polyadenylated mRNA from cell lines was prepared by the  
25 proteinase K/SDS method (Gonda, T.J. et al., Molec. Cell.  
Biol. 2:617-624 (1982)). Samples of mRNA were resolved  
by electrophoresis on 1% agarose-2.2M formaldehyde gels,  
blotted onto nylon membranes (Biotrans, ICN) and incubated  
with the 2.9 kb insert of clone Re-OF labeled with <sup>32</sup>P by

random priming as probe (Sambrook, J. et al., Molecular Cloning: A Laboratory Manual, 2d Ed., Cold Spring Harbor, NY, Cold Spring Harbor Laboratory Press, (1989). Hybridizations were performed at 42°C in hybridization  
5 buffer containing 50% formamide overnight, and blots were washed at 55°C in 0.2X SSC, 0.1% SDS, before exposure to X-AR film at -70°C.

Example 1. Production of Anti-Type III Receptor Protein  
Antibodies and Microsequencing and Micro-  
10 sequencing of Peptides Resulting from Partial  
Proteolysis of Purified Type III Receptor

Initially cellular proteoglycans were purified from human placenta and then subjected to enzymatic deglycosylation with heparitinase and chondroitinase. Protein  
15 cores in the molecular weight range of 100-130 kilodaltons were further purified by preparative gel electrophoresis; these should include the type III receptor. This partially purified material was used as an immunogen in mice. After screening 850 hybridoma lines developed  
20 from immunized mice, three lines were found to produce antibodies that specifically recognized and immunoprecipitated a deglycosylated polypeptide species of 100-120 kD. This species could be radiolabelled by incubation of whole cells with <sup>125</sup>I-TGF-β followed by  
25 covalent cross-linking. Its size is consistent with that of the protein core previously reported for the type III receptor. (Massague, J., Annu. Rev. Cell. Biol. 6:597-641 (1990))

Monoclonal antibody 94 was used to purify the type  
30 III receptor from rat liver by affinity-chromatography.

The purified receptor was subjected to partial proteolysis and the resulting peptides were resolved by high pressure liquid chromatography. Several peptides were subjected to microsequencing and yielded the following oligopeptide sequences:

Peptide I: ILLDPDHPPAL      Peptide II: QAPFPINFMIA  
Peptide III: QPIVPSVQ      Peptide IV: FYVEQGYGR

These peptide sequences were used to construct degenerate oligonucleotides that served either as primers in a cloning strategy using the polymerase chain reaction (PCR) or as probes in screening cDNA libraries. While this strategy was not productive, the oligopeptide sequences proved useful in verifying the receptor clones isolated by the second, alternative strategy (see Example 2).

Example 2. Expression Cloning of the Type III Receptor cDNA

An expression cloning strategy in COS cells, a procedure which takes advantage of the considerable amplification of individual cDNAs in transfected COS cells was used as an alternative means to isolate TGF- $\beta$  receptor clones. Such amplification is mediated by SV40 large T antigen expressed by the COS cells interacting with a SV40 origin of replication in the cDNA vector. Gearing, D. et al., EMBO J. 8:3667-3676 (1989); Lin, H.Y., et al., Proc. Natl. Acad. Sci. 88:3185-3189



(1991a); Lin, H. Y. et al., Science, in press (1991); Mathews, L. S. and Vale, W. W., Cell 65:973-982 (1991).

The strategy involved the construction of a cDNA library from A-10 cells, a rat vascular smooth muscle cell line that expresses all three high-affinity TGF- $\beta$  receptors. The resulting cDNAs were inserted into the vector pcDNA-1, which carries the CMV transcriptional promoter and the SV40 origin of replication. The resulting library was then divided into pools of 10,000 independent recombinants each and DNA from each pool was transfected into  $1.5 \times 10^6$  COS-7 cells grown on glass flaskettes by means of DEAE-dextran transfection procedure. Aruffo, A. and Seed, B., Proc. Natl. Acad. Sci., U.S.A. 84:8573-8577 (1987); Gearing, D. et al., EMBO J. 8:3667-3676 (1989); Mathews, L. S. and Vale, W. W., Cell 65:973-982 (1991). The transfected cells were cultured for 48-60 hours and then exposed to radiolabelled TGF- $\beta$ 1 for four hours. Following this treatment, the glass slides carrying these cells were washed extensively and fixed. These slides were dipped in liquid photographic emulsion and examined by darkfield microscopy. While all of the receptor genes cloned to date by this procedure have undetectable or low constitutive levels of expression in COS cells, we were hindered by the fact that untransfected COS cells already express substantial amounts of type III TGF- $\beta$  receptor. Such expression, estimated to be approximately  $2 \times 10^5$  receptor molecules per cell, might well have generated an unacceptably high level of background binding. However, since the detection procedure involves visualizing radiolabelled ligand-binding on individual cells, it was hoped that

identifying occasional cells expressing substantially higher levels of vector-encoded receptor would be possible. This hope was vindicated in the initial experiments.

5       After screening nearly one million cDNA clones in this manner, a glass slide containing 20 positive transfectants was identified. The original pool of expression constructs from which one such transfectant was derived was split into 25 subpools of 1000 clones each and these  
10       were subjected to a second round of screening. Two further rounds of sib-selection resulted in the isolation of a cDNA clone (R3-OF) with a 2.9 kb insert that induced high levels of TGF- $\beta$ -binding proteins in approximately 10% of COS cells into which it was transfected.

15       The specificity of this binding was validated by showing that addition of a 200-fold excess of unlabeled TGF- $\beta$  competitor strongly reduced binding of <sup>125</sup>I-TGF- $\beta$  to transfected cells. By taking into account a transfection efficiency of 10% and the high background of  
20       endogenous receptor expression, we calculated that the level of total <sup>125</sup>I-TGF- $\beta$  binding to each glass slide of cells transfected with this cDNA clone (Figure 1C) was only 2-fold above the level seen with mock transfectants (data not shown). Nonetheless, this marginal increase in  
25       ligand-binding was sufficient to identify rare transfectants amidst a large field of cells expressing this background level of receptor.

30       The R3-OF cDNA encoded an open reading frame of 836 amino acid residues of which the 3' most 18 were encoded by vector sequence, clearly indicating that clone R3-OF was an incomplete cDNA insert which ended prematurely at

the codon specifying alanine 818 (Figure 4). R3-OF was used as a probe to isolate a full-length cDNA from a rat 208F lambda phage library. This clone, termed R3-OFF, was 6 kb in length and encoded a protein of 853 amino acids; its sequence was co-linear with that of clone R3-OF.

Example 3. Characterization of the Product of the Full Length Clone R3-OFF

Characterization of the product of the full length clone R3-OFF was undertaken in order to determine which of the three TGF- $\beta$  receptors it specified. To do so, COS transfectants were incubated with radioiodinated TGF- $\beta$ , chemical crosslinker was added and the labelled receptors were resolved by polyacrylamide gel electrophoresis.

Labelling of cell surface TGF- $\beta$  receptors in this way resulted in the detection of three distinct species on the surface of COS cells, as extensively by others (Massague, J. et al., Ann. NY Acad. Sci. 593:59-72 (1990). These included the two lower molecular weight type I and II receptors (65 and 85 kD) and the higher molecular weight type III proteoglycan, which migrated as a diffuse band of 280-330 kd. Enzymatic treatment of the proteoglycan with chondroitinase and heparitinase yielded a core protein of approximately 100 kd. Binding to all three receptor types was specific, in that it was completed by 200-fold excess of unlabeled TGF- $\beta$ 1.

Transfecting the R3-OFF cDNA caused a two-fold increase in expression of the type III receptor. When a cell lysate derived from COS cells transfected with clone R3-OFF was treated with deglycosylating enzymes, the

heterogenous 280-330 kd band was converted to a protein core which co-migrated with the type III protein core seen in untransfected A10 cells. Importantly, the recombinant protein core migrates differently from the endogenous COS cell type III protein core.

These observations were confirmed and extended in experiments using stably transfected cells expressing the R3-OFF cDNA. L6 rat skeleton muscle myoblasts normally do not express detectable type III mRNA or endogenous type III receptor (determined by radiolabelled ligand-binding assay). Such cells were transfected with the isolated cDNA in the vector pcDNA-neo. Cell clones stably expressing this clone in both the forward and reverse orientations with respect to the CMV promoter were isolated and analyzed by ligand binding assay.

Introduction of either the full length clone R3-OFF or the partial clone R3-OF in the forward orientation led to the de novo expression of the type III receptor. L6 cells transfected with the cDNA in reversed orientation did not express this protein. The apparent size of the protein core of the type III receptor in cells transfected with the R3-OF clone is smaller than that expressed by R3-OFF transfected cells, consistent with the difference in the sizes of the protein cores predicted from the respective nucleic acid sequences (Figure 1).

Unexpectedly the amount of radio-labelled ligand cross-linked to the type II receptor is increased by 2.5 fold in cells expressing the type II cDNA, while the amount cross-linked to the type I receptor remained unchanged. This apparent specific up-regulation of

ligand-binding to the type II receptor could be detected with all of the 15 stably transfected L6 cell lines analyzed so far. This effect seems to be mediated by the truncated clone R3-OFF which lacks the cytoplasmic domain as well as by the full-length clone R3-OFF.

Example 4. Expression of Type III Receptor

Northern blot analysis demonstrated that the type III receptor mRNA is expressed as a single 6 kb message in several rat tissues. The level of mRNA expression in the liver was less than in other tissues, a result expected from earlier surveys of various tissues using radioiodinated TGF- $\beta$ 1. Based on this information, it appears that clone R3-OFF, with a ~6 kb cDNA insert, represents a full length rat type III cDNA clone.

Cells of mouse origin (MEL and YH16) appear to express a smaller (~5.5 kb) message for the type III mRNA than those of pig, rat and human origin. In all of these cells, expression or absence of the type III mRNA is consistent with the expression or absence of detectable cell surface type III receptors with the notable exception of the retinoblastoma cell lines (Y79, Weri-1, Weri-24, and Weri-27). These cells have previously been shown to lack detectable surface expression of type III receptor, a result confirmed by our own unpublished work. It is striking that the type III receptor mRNA is expressed in these cells at a level comparable to that of other cells that do indeed express type III receptor proteins at readily detectable levels. At this moment, we can only conclude that TGF- $\beta$  receptor III expression, which is substantial in normal retinoblasts (AD12), has

been down-regulated in these retinoblastoma tumor cells, perhaps through post-transcriptional mechanisms.

Example 5. Sequence Analysis of the Full-Length Type  
III cDNA

5       The full-length cDNA clone (R3-OFF), described in  
Example 4, was subjected to sequence analysis. The full  
reading frame along with flanking sequences is presented  
in Figure 1. This reading frame encodes a protein of 853  
amino acid residues, which is compatible with the 100 kD  
10       observed for the fully deglycosylated TGF- $\beta$  type III  
receptor.

Two segments of derived protein sequence (underlined  
and italicized, residues 378-388 and 427-434) precisely  
match those determined earlier from direct biochemical  
15       analysis of the purified receptor protein. This further  
secured the identity of this isolated cDNA clone as  
encoding the rat type III receptor.

This TGF- $\beta$  binding protein has an unusual structure  
for a cytokine receptor. Hydropathy analysis indicates a  
20       N-terminal signal sequence, followed by a long,  
hydrophilic N-terminal region (Kyte, J. and R. F.  
Doolittle, J. Mol. Biol. 157:105-132 (1982)). A 27  
residue region of strong hydrophobicity (underlined,  
residues 786-812) toward the C-terminus represents the  
25       single putative transmembrane domain. This suggests that  
nearly all of the receptor is composed of an N-terminal  
extracellular domain that is anchored to the plasma  
membrane near its C-terminus. A relatively short  
C-terminal tail of 41 residues represents the putative  
30       cytoplasmic domain.

The clone R3-OF was also analyzed and found to be a truncated version of R3-OFF, with an identical open reading frame but whose last encoded residue is alanine 818 (Figure 1).

5 In R3-OFF there are six consensus N-linked glycosylation sites and 15 cysteines (indicated in Figure 1). There is at least one consensus glycosaminoglycan addition site at serine 535 (Bernfield, M. and K. C. Hooper, Ann. N.Y. Acad. Sci. in press (1991), and  
10 numerous Ser-Gly residues that are potential sites for GAG conjugation. A consensus protein kinase C site is also present at residue 817.

Only one other gene described to date, a glycoprotein expressed in high quantities by endothelial  
15 cells and termed endoglin (Gougos and Letarte, 1990), contains a related amino acid sequence. Overall, there is ~30% identity with the type III receptor over the entire 645 amino acid residue length of endoglin. The most homologous regions between the sequences of the type  
20 III receptor and endoglin (74% identity) falls primarily in the putative transmembrane and cytoplasmic domains. Similar to the general structure of type III receptor, endoglin is a glycoprotein which contains a large hydrophilic and presumably extracellular N-terminal  
25 domain followed by a putative transmembrane domain and a short cytoplasmic tail of 47 amino acid residues. The biological role of endoglin is unclear, though it has been suggested that it may involve cell-cell recognition through interactions of an "RGD" sequence on its  
30 ectodomain with other adhesion molecules. Unlike the

Equivalents

Those skilled in the art will recognize, or be able  
5 to ascertain using not more than routine experimentation,  
many equivalents to the specific embodiments of the  
invention described herein. Such equivalents are  
intended to be encompassed by the following claims.



CLAIMS

1. Isolated DNA encoding TGF- $\beta$  receptor of vertebrate origin or DNA which hybridizes thereto and encodes TGF- $\beta$  receptor of vertebrate origin.
- 5 2. Isolated DNA of Claim 1 wherein the TGF- $\beta$  receptor is TGF- $\beta$  type III receptor or TGF- $\beta$  type II receptor.
3. Isolated DNA of Claim 2 which is of mammalian origin.
- 10 4. Isolated DNA of murine or human origin encoding TGF- $\beta$  type III receptor or DNA which hybridizes thereto.
- 15 5. Isolated DNA of Claim 4 having the nucleotide sequence of Figure 1 or a portion thereof sufficient to encode TGF- $\beta$  type III receptor.
6. Isolated DNA of murine or human origin encoding TGF- $\beta$  type II receptor or DNA which hybridizes thereto.
- 20 7. Isolated DNA of Claim 6 having the nucleotide sequence of Figure 2 or a portion thereof sufficient to encode TGF- $\beta$  type II receptor.
8. Isolated TGF- $\beta$  type III receptor of mammalian origin.

9. Isolated TGF- $\beta$  type III receptor of Claim 8 having the amino acid sequence of Figure 1 or a substantially similar amino acid sequence.
10. Isolated TGF- $\beta$  type II receptor of mammalian origin.
- 5 11. Isolated TGF- $\beta$  type II receptor of Claim 10 having the amino acid sequence of Figure 3 or a substantially similar amino acid sequence.
12. Recombinant TGF- $\beta$  type III receptor of mammalian origin.
- 10 13. Recombinant TGF- $\beta$  type III receptor of Claim 8 having the amino acid sequence of Figure 1 or a substantially similar amino acid sequence.
14. Recombinant TGF- $\beta$  type II receptor of mammalian origin.
- 15 15. Recombinant TGF- $\beta$  type II receptor of Claim 10 having the amino acid sequence of Figure 4 or a substantially similar amino acid sequence.
16. Soluble TGF- $\beta$  receptor.
17. Soluble TGF- $\beta$  receptor of Claim 16 which is soluble  
20 TGF- $\beta$  type III receptor.
18. Soluble TGF- $\beta$  type III receptor of Claim 17 in which the amino acid sequence is amino acids 1 through

785, inclusive, of Figure 1 or a substantially similar amino acid sequence.

19. Soluble TGF- $\beta$  receptor of Claim 16 which is soluble TGF- $\beta$  type II receptor.

5 20. Soluble TGF- $\beta$  receptor of Claim 19 in which the amino acid sequence is approximately amino acids 1 through 166, inclusive, of Figure 3, or a substantially similar amino acid sequence.

10 21. An antibody which specifically recognized TGF- $\beta$  type III receptor of mammalian origin.

22. An antibody of Claim 21 which is a monoclonal antibody.

23. An antibody which specifically recognizes soluble TGF- $\beta$  type III receptor of mammalian origin.

15 24. An antibody which specifically recognizes soluble TGF- $\beta$  type II receptor of mammalian origin.

20 25. A method of altering TGF- $\beta$  binding to TGF- $\beta$  type III receptor on the surface of a cell, comprising combining soluble TGF- $\beta$  type III receptor with the cell, under conditions appropriate for binding of the soluble TGF- $\beta$  type III receptor and TGF- $\beta$ .

26. The method of Claim 25 wherein TGF- $\beta$  binding is inhibited.

27. A method of altering TGF- $\beta$  binding to TGF- $\beta$  type II receptor on the surface of a cell, comprising combining soluble TGF- $\beta$  type II receptor with the cell, under conditions appropriate for binding of the soluble TGF- $\beta$  type II receptor and TGF- $\beta$ .
28. The method of Claim 27 wherein TGF- $\beta$  binding is inhibited.
29. A method of altering TGF- $\beta$  binding to TGF- $\beta$  type III receptor on the surface of a cell comprising combining the cell with DNA encoding TGF- $\beta$  type III receptor in an appropriate expression system which expresses TGF- $\beta$  type III receptor, under conditions appropriate for expression of TGF- $\beta$  type III receptor and binding of TGF- $\beta$  with TGF- $\beta$  type III receptor.
30. A method of regulating the effect of TGF- $\beta$  in a mammal, comprising administering to the mammal a TGF- $\beta$  receptor selected from the group consisting of: TGF- $\beta$  type III receptor, TGF- $\beta$  type II receptor, soluble TGF- $\beta$  type III receptor, soluble TGF- $\beta$  type II receptor, TGF- $\beta$  bound to TGF- $\beta$  type III receptor or a combination thereof, in sufficient quantity to alter binding of TGF- $\beta$  to TGF- $\beta$  type III receptor, binding of TGF- $\beta$  to TGF- $\beta$  type II receptor or both.

ABSTRACT

DNA encoding TGF- $\beta$  TYPE III receptor of mammalian origin, DNA encoding TGF- $\beta$  type II receptor of mammalian origin, TGF- $\beta$  type III receptor, TGF- $\beta$  type II receptor and uses therefor.

5

SECRET

FIGURE 1

-240  
CAGGAGGTGAAAGTCCCCGGCGGTCCGGATGGCGCAGTTGCACTGCGCTGCTGAGCTCGCGGCCCGCTCGGCACACTGGGGGGACTCGCTTCGGCTAGTAACCTCCACCTCGCGGCGG -121  
ACGACCGGTCTGGACACGCTCGCTCGGAGGCAAGTTGAACAGTGCAGAGAAGGATCTTAAAGCTACACCGGACTTGCCACGATTGCGCTCAATCTGAAGAACCAAGGCTGTTGGAGAG -1  
ATGGCAGTGACATCCACCACATGATCCCGGTGATGGTTGCTCTGATGAGCGCCTGCTGGCCACCGCGGCTCCAGAGCCAGCAGCCCGGTGTGAACGTGTACCAATCAACGCCTCTCAC 120  
MetAlaValThrSerHisHisMetIleProValMetValValLeuMetSerAlaCysLeuAlaThrAlaGlyProGluProSerThrArgCysGluLeuSerProIleAsnAlaSerHis 40  
CCAGTCCAGGCCCTTGATGGAGAGCTTACCGCTTCTGCTGCTGGCTGTGCCAGCAGAGGCCACCGCGGCTGCCAAGGGAGGTCCATGTCTAAACCTCCGAAGTACAGATCAGGGACCGGC 240  
ProValGlnAlaLeuMetGluSerPheThrValLeuSerGlyCysAlaSerArgGlyThrThrGlyLeuProArgGluValHisValLeuAsnLeuArgSerThrAspGlnGlyProGly 80  
CAGCGGCAGAGAGAGGTTACCTGACCTGAACCCCATTCGCTCGGTGCACACTCACCACAAACCTATCGTGTCTGCTCAACTCCCCCAGCCCCCTGGTGTGGCATCTGAAGACGGAG 360  
GlnArgGlnArgGluValThrLeuHisLeuAsnProIleAlaSerValHisThrHisHisLysProIleValPheLeuLeuAsnSerProGlnProLeuValTrpHisLeuLysThrGlu 120  
AGACTGGCGCTGGTGTCCCCAGACTCTTCCTGGTTTCGGAGGGTTCTGTGGTCCAGTTTCCATCAGGAACTTCTCCTTGACAGCAGAAACAGAGGAAAGGAATTTCCCTCAAGAAAT 480  
ArgLeuAlaAlaGlyValProArgLeuPheLeuValSerGluGlySerValValGlnPheProSerAlaAsnPheSerLeuThrAlaGluThrGluGluArgAsnPheProGlnGluAsn 160  
GAACATCTCGTGGCGTGGGCCCAAAGGAATATGGAGCAGTGACTTCGTTCTACTGAACCTCAAGATAGCAAGAAACATCTATATAAAGTGGGAGAAGATCAAGTGTTCCTCTCAGTGT 600  
GluHisLeuValArgTrpAlaGlnLysGluTyrGlyAlaValThrSerPheThrGluLeuLysIleAlaArgAsnIleTyrIleLysValGlyGluAspGlnValPheProProThrCys 200  
AACATAGGGAAGAAATTTCTCTCACTCAATTACCTTGCCGAGTACCTTCAACCCAAAGCCGCGAAGGTTGTGCTGCTGCCAGTCAGCCCCATGAAAGGAAGTACACATCATCGAGTTA 720  
AsnIleGlyLysAsnPheLeuSerLeuAsnTyrLeuAlaGluTyrLeuGlnProLysAlaAlaGluGlyCysValLeuProSerGlnProHisGluLysGluValHisIleIleGluLeu 240  
ATTACCCCGAGCTCGAACCTTACAGCGCTTTCCAGGTGGATATAATAGTTGACATACGACCTGCTCAAGAGGATCCGAGGTGGTCAAAACCTTGCTCTGATCTTGAAGTGCAAAAG 840  
IleThrProSerSerAsnProTyrSerAlaPheGlnValAspIleIleValAspIleArgProAlaGlnGluAspProGluValValLysAsnLeuValLeuIleLeuLysCysLysLys 280  
TCTGCTCACTGGGTGATCAAGTCTTTTACGCTCAAGGGAACCTTGAAGTCAATTGCTCCCAACAGTATCGGCTTTGAAAAGAGAGTGAACGATCCATGACAATGACCAATTTGGTAA 960  
SerValAsnTrpValIleLysSerPheAspValLysGlyAsnLeuLysValIleAlaProAsnSerIleGlyPheGlyLysGluSerGluArgSerMetThrMetThrLysLeuValArg 320  
GATCAGATCCCTTCCACCAAGAGAATCTGATGAAGTGGGCACTGGCAATGGCTACAGGCCAGTGACGTACACAAATGGCTCCCGTGGCTAATAGATTTTCATCTTCGGCTTGAGAAC 1080  
AspAspIleProSerThrGlnGluAsnLeuMetLysTrpAlaLeuAspAsnGlyTyrArgProValThrSerTyrThrMetAlaProValAlaAsnArgPheHisLeuArgLeuGluAsn 360  
AAGGAGGAGATGAGAGATGAGGAAGTCCACACCATTCCTCCTGAGCTTCGTATCTGCTGGACCTGACCAACCGCCCGCCCTGGACAAOCCACTCTTCCAGGAGAGGGAAGCCCAAT 1200  
AsnGluGluMetArgAspGluGluValHisThrIleProProGluLeuArgIleLeuLeuAspProAspHisProProAlaLeuAspAsnProLeuPheProGlyGluGlySerProAsn 400  
GGTCTCTCCCTTTCCATTCOCGGATATCCCCAGGAGAGGCTGGAAGGAGGGCGAAGATAGGATCCCGCGCCAAAGCAGGCCCATCGTTCCAGTGTTCACCTGCTTCTGACCACCGA 1320  
GlyGlyLeuProPheProPheProAspIleProArgArgGlyTrpLysGluGlyGluAspArgIleProArgProLysGlnProIleValProSerValGlnLeuLeuProAspHisArg 440  
GAAACAGAAGAAGTGAAGGGGGCTGGACATCGCCCTGTCAGTCAATGTGACCATGAAAGAGTGGTCTGGCTGTAGACAAAGACTCTTCCAGACCAATGGCTACTCAGGGATGGAG 1440  
GluProGluGluValGlnGlyGlyValAspIleAlaLeuSerValLysCysAspHisGluLysMetValValAlaValAspLysAspSerPheGlnThrAsnGlyTyrSerGlyMetGlu 480  
CTGACCTGTTGGATCCTTCGTGTAAGGCCAAAATGAATGGTACTACTTTGTTCTCGAGTCTCCCTGAATGGCTGTGGTACTCGACATCGGAGGTGACCCCGGATCGTGGTTTAC 1560  
LeuThrLeuLeuAspProSerCysLysAlaLysMetAsnGlyThrHisPheValLeuGluSerProLeuAsnGlyCysGlyThrArgHisArgArgSerThrProAspGlyValValTyr 520  
TATCTCTATTGTTGGTGCAGGCTCCGTCCTCGGATACGAGTGGCTGGCTGATGGCTATGAAGACTTGGAGTCAAGGCGAATAGGATTCTGGAGACGGGGATGAAGAGAAACT 1680  
TyrAsnSerIleValValGlnAlaProSerProGlyAspSerSerGlyTrpProAspGlyTyrGluAspLeuGluSerGlyAspAsnGlyPheProGlyAspGlyAspGluGlyGluThr 560  
CCCCCTGAGCCGAGCTGGAGTGGTGGTGTAACTGACAGCTTCGCGCAGCTGAGGAATCCCACTGGCTTCAGGGCCAGCTCGATGGAATGCTACCTTCAACATGGAGCTGTATAAC 1800  
AlaProLeuSerArgAlaGlyValValValPheAsnCysSerLeuArgGlnLeuArgAsnProSerGlyPheGlnGlyGlnLeuAspGlyAsnAlaThrPheAsnMetGluLeuTyrAsn 600  
ACAGACCTCTTCTGGTGCCCTCCCAAGGGCTCTCTCTGTGGCAGAGAAGCAGCATGTTATGTTGAGGTGTCTGTACCAAGGCTGACCAAGATCTGGGATTCGCCATCCAAACCTGC 1920  
ThrAspLeuPheLeuValProSerProGlyValPheSerValAlaGluAsnGluHisValTyrValGluValSerValThrLysAlaAspGlnAspLeuGlyPheAlaIleGlnThrCys 640  
TTTCTCTCTCATACTCCAACCCAGACAGAATGTCTGATTACACCATCATCGAGAATCTGTCCGAAAGCAGCACTGTGAAGTTCTACAGCTCCAAGAGAGTGCACCTTCCCATCCCG 2040  
PheLeuSerProTyrSerAsnProAspArgMetSerAspTyrThrIleIleGluAsnIleCysProLysAspAspSerValLysPheTyrSerSerLysArgValHisPheProIlePro 680  
CATGCTGAGGTGACAAAGAGCGCTTACGTTCTCTGTTCAGTCTGTGTTCAACACCTCCCTGCTTCTCTGCACTGCGAGTTGACTCTGTGCTCCAGGAAGAAGGGCTCCCTGAAGCTG 2160  
HisAlaGluValAspLysLysArgPheSerPheLeuPheLysSerValPheAsnThrSerLeuLeuPheLeuHisCysGluLeuThrLeuCysSerArgLysLysGlySerLeuLysLeu 720  
CCGAGGTGTGACTCTGACGACGCTGCACTTCTCTGATGCCACCATGATCTGGACCATGATGCAATAAGAAGACATTCACCAAGCCCTGGCTGTGGTCTCCAGGTAGACTAT 2280  
ProArgCysValThrProAspAspAlaCysThrSerLeuAspAlaThrMetIleTrpThrMetMetGlnAsnLysLysThrPheThrLysProLeuAlaValValLeuGlnValAspTyr 760  
AAAGAAAATGTTCCAGCACTAAGGATTCCAGTCCAATTCCTCTCTCTCTCCACAGATTTTCCATGGCTGGACACGCTCACCGTGATGGCATTGCATTTCGACGATTTGTGATCGGA 2400  
LysGluAsnValProSerThrLysAspSerSerProIleProProProProGlnIlePheHisGlyLeuAspThrLeuThrValMetGlyIleAlaPheAlaAlaPheValIleGly 800  
GCGCTCTGACGGGGGCTTGTGGTACATCTACTCCACACAGGGGAGACAGCAGGAAGGAGCAAGTCCCTACCTCGCGCCAGCCTCGGAGAACAGCAGCGCGGGCCACAGCATCGGC 2520  
AlaLeuLeuThrGlyAlaLeuTrpTyrIleTyrSerHisThrGluThrAlaArgArgGlnGlnValProThrSerProProAlaSerGluAsnSerSerAlaAlaHisSerIleGly 840  
AGCACTCAGAGTACCCCTGCTCTAGCAGCAGCAGCCTAGGTGGACAGACAGCGCCCGCCAGCCAGGGCAGGGCCCGATGCCAGTGTGCTGCTCCAGTCAAGAGTCTT 2640  
SerThrGlnSerThrProCysSerSerSerThrAla\*\*\* 853  
GATCTGGGCTCCCTGTAAGAAAGAGTGAATTTTCAATATACAGACAGCCAGTTCTACCCACCCCTTACCAAGCCACATATAATGTGACCTGGGCATCTGTACACGAAAGCTAAGCTG 2760  
GTGGCCTTCCCAACAGCCCTCGCAGGATGGGGTTTCAATGTGAACATCTGCCAGTTTGTGTTGTTTTTAAATGCTGCTTGTCCAGGTGTCCAAACATCCATCATTGGGGTGG 2880  
TCTGTTTTACAGAGTAAGGAGCGGTGAAGGGACGTAGCTAGTGTAGACCAAGGGAGACAGCTAGGATTCTCGCTAGCTGAACCAAGGTGTAATAAGAGACACGCTCC

FIGURE 2

```

>DL/3FF
Meld of: 3FF6-9 3FF13
TTCCGTTGCT GTCGGTTGGC GAGGAGTTTC CTGTTTCCCC CGCAGCGCTG
AGTTGAAGTT GAGTGAGTCA CTCGCGCGCA CGGAGCGACG ACACCCCCGC
GCGTGCACCC GCTCGGGACA GGAGCCGGAC TCCTGTGCAG CTTCCCTCGG
CCGCCGGGGG CCTCCCCGCG CCTCGCCGGC CTCCAGGCCC CTCCTGGCTG
GCGAGCGGGC GGCACATCTG GCGCGCACAT CTGCGCTGCC GGCCCGGGCG
GGGTCCGSAG AGGGCGCGGC GCGGAGGCAG CCAGGGGTCC GGGAAAGCGC
CGTCCGTGCG CTGCGGGGCTC GGTCTATGAC GAGCAGCGGG GTCTGCCATG
GGTCGGGGGC TGCTCAGGGC CTGTGGCCGC TGCACATCGT CCTGTGGACG
CGTATCGCCA GCACGATCCC ACCGCACGT CAGAAGTCGG TTAATAACGA
CATGATAGTC ACTGACAACA ACGGTGCAGT CAAGTTTCCA CAACTGTGTA
AATTTTGTGA TGTGAGATT TCCACCTGTG ACAACCAGAA ATCCTGCATG
AGCAACTGCA GCATCACCTC CATCTGTGAG AAGCCACAGG AAGTCTGTGT
GGCTGTATGG AGAAAGAATG ACGAGAACAT AACACTAGAG ACAGTTTGCC
ATGACCCCAA GCTCCCTTAC CATGACTTTA TTCTGGAAGA TGCTGCTTCT
CCAAAGTGCA TTATGAAGGA AAAAAAAG CCTGGTGAGA CTTTCTTCAT
GTGTTCCGTG AGCTCTGATG AGTGCAATGA CAACATCATC TTCTCAGAAG
AATATAACAC CAGCAATCCT GACTTGTTCG TAGTCATATT TCAAGTGACA
GGCATCAGCC TCCTGCCACC ACTGGGAGTT GCCATATCTG TCATCATCAT
CTTCTACTGC TACCGCGTTA ACCGGCAGCA GAAGCTGAGT TCAACCTGGG
AAACCGGCAA GACGCGGAAG CTCATGGAGT TCAGCGAGCA CTGTGCCATC
ATCCTGGAAG ATGACCGCTC TGACATCAGC TCCACGTGTG CCAACAACAT
CAACCACAAC ACAGAGCTGC TGCCCATTTA GCTGGACACC CTGGTGGGGA
AAGGTGCTTT TGCTGAGGTC TATAAGGCCA AGCTGAAGCA GAACACTTCA
GAGCAGTTTG AGACAGTGGC AGTCAAGATC TTTCCCTATG ACCACTATGC
CTCTTGGAAG GACAGGAAGG ACATCTTCTC AGACATCAAT CTGAAGCATG
AGAACATACT CCAGTTCCTG ACGGCTGAGG AGCGGAAGAC GGAGTTGGGG
AAACAATACT GGCTGATCAC CGCCTTCCAC GCCAAGGGCA ACCTACAGGA
GTACCTGACG CGGCATGTCA TCAGCTGGGA GGACCTGCGC AACGTGGGCA
GCTCCCTCGC CCGGGGATTG TCTCACCTCC ACAGTGATCA CACTCCATGT
GGGAGGCCCC AGATGCCCAT CGTGACACAG GACCTCAAGA GCTCCAATAT
CCTCGTGAAG AACGACCTAA CCTGCTGCCT GTGTGACTTT GGGCTTTCCC
TGCGTCTTGG ACCCTACTCT TCTGTGGATG ACCTGGCTAA CAGTGGGCAG
GTGGGAACCTG CAAGATACAT GGCTCCAGAA GTCCTAGAAT CCAGGATGAA
TTTGGAGAAT GCTGAGTCTT TCAAGCAGAC CGATGTCTAC TCCATGGCTC
TGGTGCTCTG GGAATGACA TCTCGCTGTA ATGCAGTGGG AGAAGTAAAA
GATTATGAGC CTCCATTTGG TTCCAAGGTG CGGGACCTG TGGTCGAAAG
CATGAAGGAC AACGTGTTGA GAGATCGAGG CACCAGAAAT TCCAGCTTCT
GGCTCAACCA CCAEGGOATC CAGATGGTGT GTGAGACGTT GACTGAGTGC
TGGGACCACG ACCCAGAGGC CGTCTCACA GCCCAGTGTG TGGCAGAACG
CTTCAGTGAG CTGGAGCATC TGGACAGGCT CTCGGGGAGG AGCTGCTCGG
AGGAGAAGAT TCCTGAAGAC GGCTCCCTAA ACACCTACCA ATAGCTCTTA
TGGGGCAGGC TGGGCATGTC CAAAGAGGCT GCGCCTCTCA CCAA*

```

bioRxiv preprint doi: <https://doi.org/10.1101/100000>; this version posted October 1, 2016. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

FIGURE 3

>P1;3FFPEP

Meld of: 3FF6-9 3FF13

|            |            |            |            |            |
|------------|------------|------------|------------|------------|
| MTSSGVCHGS | GAAQGLWPLH | IVLWTRIAST | IPPHVQKSVN | NDMIVTDNNG |
| AVKEPQLCKF | CDVRFSTCDN | QKSCMSNCSI | TSICEKPQEV | CVAVWRKNDK |
| NITLETVCHD | PKLPYHDFIL | EDAASPKCIM | KEKKKPGETF | FMCSOSSDEC |
| NDNIIFSEEV | NTSNFDLLIV | IFQVTGISLL | PPLGVAISVI | IIFYCYRVNR |
| QQKLSSTWET | GKTRKIMEFS | EHCAIILEDD | RSDISSTCAN | NINHNTELLP |
| IELDTLVGKG | RFAEVYKAKL | KQNTSEQFET | VAVKIFFYDH | YASWKDRKDI |
| FSDINLKHEN | ILQFLTAEER | KTELKQYWL  | ITAFHAKGNL | QEYLTRHVIS |
| WEDLRNVGSS | LARGLSHLHS | DHTPCGRPKM | PIVHRDLKSS | NILVKNDLTC |
| CLCDFGLSLR | LGPYSSVDDL | ANSCQVGTAR | YMAPEVLESR | MNLENAESFK |
| QTDVYSMALV | LWEMTSRCNA | VGEVKDYEPF | FGSKVRDFVV | ESMKDNVLRD |
| RQTRNSSFWL | NHQGIQMVCE | TLTECWDHDP | EARLTAQCVA | ERFSELEHLD |
| RLSGRSCSEE | KIPEDGSLNT | TK*        |            |            |

bioRxiv preprint doi: <https://doi.org/10.1101/2018.04.11.243444>; this version posted April 11, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.



Declaration for Patent Application

As a named inventor, I hereby declare that:

COPY FOR CONTINUING  
APPLICATIONMy residence, post office address and citizenship are as  
stated next to my name;

I believe I am the original, first and sole inventor (if only one name is listed) or an original, first and joint inventor (if plural names are listed in the signatory page(s) commencing at page 3 hereof) of the subject matter which is claimed and for which a patent is sought on the invention entitled

TGF- $\beta$  Type Receptor cDNAa Encoded Products and Uses Therefor

the specification of which (check one)

☐ is attached hereto.

☒ was filed on October 31, 1991 as  
Application Serial No. 077786,063 (if applicable).  
and was amended on \_\_\_\_\_

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)

|                   |                    |                                 | Priority<br>Claimed             |                                |
|-------------------|--------------------|---------------------------------|---------------------------------|--------------------------------|
| _____<br>(Number) | _____<br>(Country) | _____<br>(Day/Month/Year filed) | <input type="checkbox"/><br>Yes | <input type="checkbox"/><br>No |
| _____<br>(Number) | _____<br>(Country) | _____<br>(Day/Month/Year filed) | <input type="checkbox"/><br>Yes | <input type="checkbox"/><br>No |
| _____<br>(Number) | _____<br>(Country) | _____<br>(Day/Month/Year filed) | <input type="checkbox"/><br>Yes | <input type="checkbox"/><br>No |

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

| (Application Serial No.) | (Filing date) | (Status, patented,<br>pending, abandoned) |
|--------------------------|---------------|---|
|--------------------------|---------------|---|

| (Application Serial No.) | (Filing date) | (Status, patented,<br>pending, abandoned) |
|--------------------------|---------------|---|
|--------------------------|---------------|---|

As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

I also hereby grant additional Powers of Attorney to the following attorney(s) and/or agent(s) to file and prosecute an international application under the Patent Cooperation Treaty based upon the above-identified application, including a power to meet all designated office requirements for designated states.

|                   |                         |
|-------------------|-------------------------|
| David E. Brook    | Registration No. 22,592 |
| James M. Smith    | Registration No. 28,043 |
| Leo R. Reynolds   | Registration No. 20,884 |
| Richard A. Wise   | Registration No. 18,041 |
| Patricia Granahan | Registration No. 32,227 |
| Mary Lou Wakimura | Registration No. 31,804 |
| Thomas O. Hoover  | Registration No. 32,470 |
| Alice O. Carroll  | Registration No. 33,542 |

all of Hamilton, Brook, Smith and Reynolds, P.C., Two Militia Drive, Lexington, Massachusetts 02173;

and

Send correspondence to: Patricia Granahan, Esq.  
HAMILTON, BROOK, SMITH & REYNOLDS, P.C.  
2 Militia Drive, Lexington, MA 02173

Direct telephone calls to: Patricia Granahan, Esq.

(617) 861-6240

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole  
or first inventor Herbert Y. Lin  
Inventor's  
Signature Herbert Y. Lin Date 4 Dec 1991  
Residence 550 Memorial Drive, Apt. 12D1  
Cambridge, MA 02139  
Citizenship U.S.A.  
Post Office Address same as above

Full name of second joint  
inventor, if any Xiao-Fan Wang  
Second Inventor's  
Signature Xiao-Fan Wang Date 12/6/91  
Residence 872 Massachusetts Avenue, Apt. 401  
Cambridge, MA 02139  
Citizenship Peoples Republic of China  
Post Office Address same as above

Full name of third joint  
inventor, if any Robert A. Weinberg  
Third Inventor's  
Signature Robert A. Weinberg Date 12/4/91  
Residence 25 Copley Street  
Brookline, MA 02146  
Citizenship U.S.A.  
Post Office Address same as above

Full name of fourth joint  
inventor, if any Harvey F. Lodish  
Fourth Inventor's  
Signature Harvey F. Lodish Date 4 Dec 91  
Residence 1195 Fisher Avenue  
Brookline, MA 02146  
Citizenship U.S.A.  
Post Office Address same as above